Efficacy of DNK333 in Patients With COPD and Cough

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01287325
Recruitment Status : Completed
First Posted : February 1, 2011
Last Update Posted : February 1, 2011
Information provided by:

Brief Summary:
This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: DNK333 100 mg twice daily Drug: Placebo Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-centre, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Clinical Efficacy, Tolerability and Safety of Two Weeks Treatment With DNK333 100 mg Bid in Patients With COPD and Cough.
Study Start Date : September 2003
Actual Primary Completion Date : April 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cough

Arm Intervention/treatment
Experimental: DNK333 Drug: DNK333 100 mg twice daily
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Self-reported cough [ Time Frame: At 2 weeks ]

Secondary Outcome Measures :
  1. Sensitivity to capsaicin challenge [ Time Frame: At 2 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mild to moderate COPD
  • Forced expiratory volume in 1 second (FEV1) ≥30% predicted
  • FEV1/FVC (forced vital capacity) <70%
  • Significant amount of cough and minimal amount of sputum production, both as judged by self reporting

Exclusion criteria:

  • Upper or lower airway infection within 4 weeks prior to screening
  • COPD exacerbation within 4 weeks prior to screening
  • Past history or current diagnosis of congestive heart failure, cirrhosis or hepatic failure
  • History of lung cancer or pulmonary resection/thoracic radiotherapy

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01287325

Novartis Investigative Site
Zuidlaren, Netherlands
United Kingdom
Novartis Investigative Site
London, United Kingdom
Sponsors and Collaborators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT01287325     History of Changes
Other Study ID Numbers: DNK333C2201
First Posted: February 1, 2011    Key Record Dates
Last Update Posted: February 1, 2011
Last Verified: January 2011

Keywords provided by Novartis:
Chronic obstructive pulmonary disease

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases